Investor rights law firm Halper Sadeh LLC is investigating three companies for potential federal securities law violations and breaches of fiduciary duties related to their merger transactions: Astria Therapeutics' sale to BioCryst Pharmaceuticals, Green Dot Corporation's sale to Smith Ventures and CommerceOne Financial Corporation, and United Security Bancshares' sale to Community West Bancshares. The firm is seeking increased consideration for shareholders and additional disclosures on a contingent fee basis.

Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches in several corporate sales involving trueCar, Akero Therapeutics, PotlatchDeltic, and Astria Therapeutics.

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.

The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. InnSuites Hospitality Trust The Trade: InnSuites Hospitality Trust (NYSE:

Astria Therapeutics (ATXS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Improvement in production and lower costs are likely to have buoyed the third-quarter earnings of Suncor Energy (SU), only to be offset by a drop in realized prices.

Patterson-UTI Energy (PTEN) beat the Zacks Consensus Estimate for earnings thrice in the last four quarters and met in the other, resulting in an earnings surprise of 20.5%, on average.

Astria Therapeutics (NASDAQ:ATXS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 These 4 analysts have an average price target of $20.25 versus the current price of Astria Therapeutics at $6.4, implying upside. Below is a summary of how these 4 analysts rated Astria Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ...Full story available on Benzinga.com